GET THE APP

Important advance in targeted therapies in breast cancer
..

Metabolomics:Open Access

ISSN: 2153-0769

Open Access

Important advance in targeted therapies in breast cancer


7th International Conference and Expo on Metabolomics

November 14-16, 2016 Orlando, Florida, USA

Moumita Chatterjee

Campana Cancer Center, Argentina

Posters & Accepted Abstracts: Metabolomics

Abstract :

It took more than 15 years since the approval of trastuzumab, the first monoclonal antibody created to attack a type of breast cancer tumor cells overexpress the HER2 protein. Since its discovery almost free survival disease progression in those with this particularly aggressive tumor that affects 1 in 5 women diagnosed with breast cancer she tripled. This is the biggest breakthrough in targeted therapy and those patients who really are effective treatments, it can say that he became in those cases where successful treatment is called as individualized medicine. These new treatments, managed to triple the disease-free survival in patients with an aggressive variant of breast cancer. Trastuzumab was the first monoclonal antibody specifically created to attack tumor cells that over-express the HER2 protein, when this protein is produced in excessive amounts, transmits signals to cells to divide, multiply and grow faster normal cells, contributing thus to the onset and progression of cancer. When trastuzumab binds to HER2 it prohibits the proliferation of these cells. Its mechanism activates the immune system of the body and blocks the HER2 signaling pathway to selectively destroy tumor cells. Since it was first authorized in 1998, more than one million three hundred thousand women with HER2-positive tumors have been treated with this drug.Important and worthy news about the new way to manage Trastuzumab. This is currently administered intravenously (IV) but significant scoop is already authorized in Europe since 2015, a subcutaneous formulation (SC). The administration intravenously required about 30-90 minutes being weekly. While the novel form of subcutaneous administration involves an injection current of only five minutes. This allows patients a better quality of life, being more beneficial from the point of hospital view, since it does not require an IV, patients need not be admitted during application, as well as decreases the risk of infections minimum. Given this new form of subcutaneous administration, it allows this much easier and better accepted by patients� parts.The result obtained using subcutaneous Herceptin is that it could be reduced by a greater percentage than 50% the time spent by health personnel to prepare and administer the medication. This new formula SC does not require dose adjustment depending on the body surface of the patient, as the dose is fixed, and it does not require initial loading dose. It is indisputable that all this has a very positive and important impact for patient comfort it provides treatment and increased comfort suffering from breast cancer, thereby promoting improved quality of life and greater acceptance by patients when applicable

Biography :

Email: dcapdepon@yahoo.com.ar

Google Scholar citation report
Citations: 895

Metabolomics:Open Access received 895 citations as per Google Scholar report

Metabolomics:Open Access peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward